Bendamustine 25 Mg Fresenius, Bendamustine 100 Mg Fresenius 25 mg, 100mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 10 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for specific leukemias and lymphomas.
Dosage (summary)
100 mg/mu00b2 for CLL; 90 mg/mu00b2 for NHL with rituximab; 120-150 mg/mu00b2 for multiple myeloma.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Live vaccines
- QT prolonging drugs
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Severe bone marrow suppression
- Infections
- Jaundice
Common side effects
- Myelosuppression
- Infections
- Skin reactions
Counselling Points
- Monitor for infections
- Report skin reactions
- Avoid live vaccines
Serious warnings
- Myelosuppression
- Hepatitis B reactivation
- Severe skin reactions
Important Disclaimer
The Bendamustine 25 Mg Fresenius, Bendamustine 100 Mg Fresenius 25 mg, 100mg Powder for concentrate for solution for infusion professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
